Coronavirus: EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab)
5 March 2021 – EMA’s human medicines committee (CHMP) has completed its review on the use of the monoclonal antibodies casirivimab and imdevimab to treat patients with COVID-19. This review was undertaken to provide a harmonised scientific opinion at EU level to support national decision making on the possible use of the antibodies prior to marketing authorisation. Preliminary results indicate that the combination reduced the viral load (amount of virus in the back of the nose and throat) more than placebo. The Agency concluded that the combination also known as REGN-COV2 can be used for the treatment of confirmed COVID-19 patients who do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.
For more information, see here.